Efficacy of Intravitreal Bevacizumab for macular edema secondary to Branch retinal vein occlusion

Abstract

Background: Branch retinal vein occlusion is the 2nd most common retinal vascular disease after diabetic retinopathy. The most common cause
of visual impairment in BRVO patient is macular edema. Purpose: To evaluate the efficacy of Intravitreal injections of Bevacizumab in patients
with macular edema secondary to BRVO. Methods: All the patients> 18yrs of age with macular edema secondary to BRVO who had treated
with Intravitreal Bevacizumab (1.25mg/0.05ml) were analyzed retrospectively. Clinical variables including BCVA, CMT, number of injections
and complications were analyzed. Results: 23 eyes of 23 patients (11M/12F) were included in study. The mean follow-up period was 5.8±1.7
months. The mean baseline (log MAR) VA was 0.58±0.17 which was significantly improved to 0.36±0.13 at 1 month and 0.33±0.12 at 3 months.
The mean CMT at the onset was 355±28.73μm which reduced to 297±28.17μm after 2 weeks of injection and 291±27.13μm at 1 month. Patients
had given an average of 2 injections. There were no adverse effects observed following injections. Conclusion: It showed a significant reduction
in Central macular thickness and improvement in BCVA.